Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 21.17 as of 2026-09-24T19:45:45.608Z.
Consensus retrieved: 2026-09-13T22:39:00.665Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-24T19:45:45.608Z.
Quote observation: 2026-09-24T19:45:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d11bd6014c51ff39f57781dc4a396c363117c8a3ee6656185d1e516709bf1d1f
Forward PE Ratio (21.17) = Dated Quote Price ($236.95) / Consensus Forward EPS ($11.19)
FORWARD PE RATIO
21.17
SECTOR MEDIAN · HEALTHCARE
18.80
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+12.61%
vs the sector median at left
Quest Diagnostics Incorporated
Market Cap
$26.15B
Forward PE Ratio
21.17
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $26.15B | 21.17 |
| West Pharmaceutical Services, Inc. (WST)vs › | $26.32B | 41.70 |
| Labcorp Holdings Inc. (LH)vs › | $25.35B | 16.85 |
| Incyte Corporation (INCY)vs › | $25.17B | 33.01 |
| BioNTech SE (BNTX)vs › | $25.07B | N/A |
| Medline Inc. (MDLN)vs › | $29.31B | 23.22 |
| Zoetis Inc. (ZTS)vs › | $29.39B | 11.21 |
| GE HealthCare Technologies Inc. (GEHC)vs › | $29.99B | 13.48 |
| Centene Corp. (CNC)vs › | $30.57B | 12.89 |
| Mettler-Toledo International Inc. (MTD)vs › | $30.87B | 32.28 |
Trailing P/E
25.1
reported TTM EPS
Forward P/E
21.2
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $11.19 implies +18.8% EPS growth vs the reported trailing $9.42.
At the dated quote price of $236.95, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $11.19 | $11.16 – $11.23 | 11 | 21.2x |
| 2027-12-31 | $12.06 | $11.82 – $12.34 | 11 | 19.7x |
| 2028-12-31 | $13.09 | $12.08 – $14.09 | 7 | 18.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
